[Effect of single nucleotide polymorphisms of RS1799937 located in WT1 gene on the pathlogical complete response to neoadjuvant chemotherapy in breast cancer patients].
Objective: To evaluate the association between single nucleotide polymorphisms (SNPs) of RS1799937 located in WT1 gene with complete response to neoadjuvant chemotherapy in breast cancer patients. Methods: 171 breast cancer patients with neoadjuvant chemotherapy were investigated to detect the RS1799937 polymorphism by sequenom method. The relationship between RS1799937 polymorphism and pathologic complete response (pCR) were analyzed by χ2 test and Fisher's exact test analysis. Predictors of pCR were analyzed using multivariate logistic regression analysis. Results: The frequency of CC, TC and TT genetype of RS1799937 was 50.3%, 41.5% and 8.2%. Of the 171 patients, pCR was achieved in 53 cases(30.9%) with CC allele 23 cases(26.7%), TC allele 23 cases(32.4%) and TT allele 7 cases(50.0%), however no statistical significant difference was observed (χ2= 3.156, P=0.204). RS1799937 polymorphism was associated with pCR in EC-T neoadjuvant therapy (χ2=6.660, P=0.033) but not in PE neoadjuvant therapy (χ2=0.473, P=0.873) cohort. Multivariate logistic regression analysis indicated that RS1799937 polymorphism, targeted therapy and clinical stage were independent predictors of pCR (P<0.05) in EC-T neoadjuvant therapy cohort. Conclusion: RS1799937 polymorphism was associated with pCR rate only in anthracycline and taxane-based neoadjuvant therapy, breast cancer patients with the rs1799937 TT allele were more likely to achieve pCR.